Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Chlorphenamine maleate
Evolan Pharma AB
R06AB; R06AB04
Chlorphenamine maleate
Solution for injection
Substituted alkylamines; chlorphenamine
Marketed
1995-06-10
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT CHLORPHENAMINE 10 mg/ml Solution for Injection (chlorphenamine maleate) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. − Keep this leaflet. You may need to read it again. − If you have any further questions, ask your doctor or nurse. − If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET : 1. What Chlorphenamine is and what it is used for 2. What you need to know before Chlorphenamine is given 3. How Chlorphenamine is given 4. Possible side effects 5. How to store Chlorphenamine 6. Contents of the pack and other information 1. WHAT CHLORPHENAMINE IS AND WHAT IT IS USED FOR Chlorphenamine 10 mg/ml Solution for Injection (i.e. injection) contains the active ingredient chlorphenamine maleate which is an antihistamine. Chlorphenamine is indicated in adults, and children (aged 1 month to 18 years) for the treatment of acute allergic reactions. These medicines inhibit the release of histamine into the body that occurs during an allergic reaction. This product relieves some of the main symptoms of a severe allergic reaction. 2. WHAT YOU NEED TO KNOW BEFORE CHLORPHENAMINE IS GIVEN YOU MUST NOT BE GIVEN CHLORPHENAMINE: • if you are ALLERGIC to chlorphenamine maleate or any of the other ingredients of this medicine (listed in section 6) • if you are in a PRE-COMA state • if you have had monoamine oxidase inhibitor (MAOI) ANTIDEPRESSIVE TREATMENT within the past 14 days. WARNINGS AND PRECAUTIONS Talk to your doctor or nurse before you are given this medicine if you: • are being treated for an OVERACTIVE THYROID or ENLARGED PROSTATE GLAND • have EPILEPSY , raised pressure within the eye or GLAUCOMA , very HIGH BLOOD PRESSURE, HEART DISEASE , LIVER DISEASE, ASTHMA or other CHEST DISEASES . Children and the elderly are more likely to experience certain side effects (see section 4) Read the complete document
Health Products Regulatory Authority 03 November 2023 CRN00DWTM Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Chlorphenamine 10 mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml of solution contains: Chlorphenamine Maleate 10 mg Excipient(s) with known effect: 2.9 mg/ml sodium (as sodium chloride). For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Solution for Injection. (Injection) Clear colourless sterile solution for injection. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Chlorphenamine is indicated in adults, and children (aged 1 month to 18 years) for the treatment of acute allergic reactions. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults_ The usual dose is 10 mg to 20 mg, with a maximum dose of 40 mg in 24 hours. _Paediatric population_ The dose for children should be calculated, based on either the child’s age or their body weight, using the following table: Age Dose 1 month to 1 year 0.25 mg/kg 1 to 5 years 2.5 mg to 5 mg OR 0.20 mg/kg 6 to 12 years 5 mg to 10 mg OR 0.20 mg/kg 12 to 18 years 10 mg to 20 mg OR 0.20 mg/kg Extra care should be taken when preparing the injection for children under 1 year due to the small volumes that are required. Dilution of chlorphenamine injection with sodium chloride intravenous infusion (0.9% w/v) should facilitate preparation. For example, diluting 0.2 ml chlorphenamine injection to 2 ml with sodium chloride 0.9% injection produces a solution containing chlorphenamine 1 mg/ml. The diluted product should be used immediately. Method of Administration Intramuscular Subcutaneous Intravenous When a rapid effect is desired, as in anaphylactic reactions, the intravenous route is recommended in addition to emergency therapy as per current standard clinical practice guidelines e.g. with adrenaline (epinephrine), corticosteroids, oxygen and supportive therapy as required. Health Products Regulatory Authority 03 November 2023 CRN00DWTM Page 2 of 5 When administered intravenou Read the complete document